Development of new indicators for the launch of a Japanese version of the NIH (4) : Refined indicators for patents linked with marketed drugs and pipelines

  • JIBU M
  • OSABE Y
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

For the sake of providing evidences that contribute to policy making or strategy planning in a Japanese version of the NIH and pharmaceutical companies, we tried to give an overview and future prospects of pharmaceutical industry based on new indicators. Here we show new indicators for identifying patents related with pharmaceutical entities' R&D progress ("Pre-clinical" arrow right "Phase 1" arrow right "Phase 2" arrow right "Phase 3" arrow right "Filed" arrow right "Approved" arrow right "Marketed"). "IPC Count", "Forward Citations", and "Citations to Non-Patent Literature" found as new indicators. Not only pipelines but also patents extracted by new indicators are considered to forecast pharmaceutical industries' power of creating new drugs.

Cite

CITATION STYLE

APA

JIBU, M., & OSABE, Y. (2014). Development of new indicators for the launch of a Japanese version of the NIH (4) : Refined indicators for patents linked with marketed drugs and pipelines. Journal of Information Processing and Management, 57(1), 29–37. https://doi.org/10.1241/johokanri.57.29

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free